List view / Grid view
New data presented at the European Society of Cardiology (ESC) Congress 2023, showed Novartis’ Leqvio® (inclisiran) provided an approximate 49 percent reduction in LDL cholesterol beyond six years of clinical observation.
Data shared at the National Lipid Association (NLA) Scientific Sessions 2023 demonstrated that obicetrapib with ezetimibe reduced low-density lipoprotein cholesterol (LDL-C) while increasing HDL-C, compared with high-intensity statin monotherapy.
In this article, Samantha Lane of the UK’s Drug Safety Research Unit discusses the development of an evidence-based medicine (EBM) methodology to assess the positive impact of withdrawing or revoking licences for medicines on public health. The approach leverages electronic health records to model the estimated number of adverse reactions…
![MIT chemical engineers have devised a new way to formulate hydrophobic drugs by turning them into a nanoemulsion, which can be poured into a mold and dried into tablets. The nanoemulsion can also be used to form small particles, seen in the vials [Credit: Felice Frankel].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MIT-HYDROPHOBIC-DRUGS-nanoemulsion-300x278.jpg)
![MIT chemical engineers have devised a new way to formulate hydrophobic drugs by turning them into a nanoemulsion, which can be poured into a mold and dried into tablets. The nanoemulsion can also be used to form small particles, seen in the vials [Credit: Felice Frankel].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MIT-HYDROPHOBIC-DRUGS-nanoemulsion-e1623151984970.jpg)
Using a new formulation technique, researchers were able to more than double drug loading of a hydrophobic active pharmaceutical ingredient in tablets. Thus, the new formulation method may lead to smaller pills delivering the same therapeutic benefit.
Researchers suggest embedding these ‘nudges’ into the electronic healthcare records to fit within the workflow of a doctor...
7 September 2016 | By Wilshire Technologies
The virtues of vegetal- vs. animal-derived actives and excipients are well-known and need no elaboration...
23 August 2016 | By Amgen
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome...
28 June 2016 | By Victoria White, Digital Content Producer
Two Phase III trials of Pfizer’s bococizumab, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint...
23 March 2016 | By Victoria White
Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo....
12 February 2016 | By Victoria White
Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs...
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
5 February 2016 | By Victoria White
The Phase 3 GAUSS-3 trial evaluating Amgen’s Repatha (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints...
18 November 2015 | By Victoria White
The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered...
28 September 2015 | By Victoria White
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy...
28 August 2015 | By Victoria White
Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, has been approved by the FDA for some patients who are unable to get their LDL cholesterol under control with current treatment options...
